BUSINESS: Sagimet’s Phase II FASCINATE-1 Clinical Study Shows TVB-2640’s Positive Impact On Patients With NASH In China And The U.S.
| | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: Sagimet’s Phase II FASCINATE-1 Clinical Study Shows TVB-2640’s Positive Impact On Patients With NASH In China And The U.S.

– Dr. Rohit Loomba to share consolidated results on November 14 in an oral presentation at American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2021 – Data from the global Phase 2 trial showed TVB-2640’s positive efficacy across diverse populations of patients in the U.S. and China – Confirmed 50 mg…

GAMES: Grounded Just Got Hotter And Hazier
| | | | | | | | | | | | | | | | | | |

GAMES: Grounded Just Got Hotter And Hazier

Today, the Grounded team released the most extensive update to the backyard with the Hot and Hazy update. From brand new biomes, new areas to explore, a handful of new insects, and some fantastic new game mechanics to help with playstyle customization, the largest addition to the backyard is certainly a hot one. Digging into…

BUSINESS: ShingaporunoDi Xia Tie SabisunoAn Quan Xing ToXin Lai Xing NoXiang Shang WoMu Zhi Shi, Bentley SystemstoSMART TrainsgaTi Xi
| | | | | | | | | | | | | | | | |

BUSINESS: ShingaporunoDi Xia Tie SabisunoAn Quan Xing ToXin Lai Xing NoXiang Shang WoMu Zhi Shi, Bentley SystemstoSMART TrainsgaTi Xi

October 12, 2021 02:03 PM Eastern Daylight Time ペンシルベニア州エクストンおよびシンガポール–(BUSINESS WIRE)–インフラストラクチャエンジニアリングソフトウェア企業のBentley Systems, Incorporated (Nasdaq:BSY)と、シンガポールのマスラピッドトランジット(MRT)運営のパイオニアであるSMRT Trains は、シンガポールで最も古いMRT路線である南北線と東西線に、予知保全意思決定支援システム(PDSS)を導入しました。 BentleyのAssetWise Linear AnalyticsをベースにしたSMRT TrainsのPDSSにより、全長282kmに及ぶ2路線の信頼性が向上し、100万kmを超える故障間隔(MKBF)を達成しました。MKBFは、信頼性の指標として世界中の鉄道事業者に使用されており、1回の故障が「5分を超えるサービス遅延」と定義されています。 PDSSが南北線と東西線に無事導入されたことを受け、SMRT Trainsはシンガポールの環状線(CCL)にもPDSSソリューションの導入を開始しました。 アジア太平洋諸都市では、大規模な地下鉄ネットワークを運営する事業者の多くが、乗客に中断のないサービスを提供できるように信頼性の向上に力を注いでいます。 そうした状況の中、Bentley SystemsとStrides Engineering(旧SMRT Services。SMRT Corporationの事業部門として、駅ベースのエンジニアリングサービスを幅広く提供)は、アジア太平洋地域で鉄道予知保全ソリューションを共同展開するという覚書(MOU)への署名を発表しました。 この覚書によりパートナーシップを確立した両社は、高度なテクノロジーと鉄道運用能力を組み合わせ、都市部の鉄道・地下鉄事業者の支援に乗り出します。覚書の条項に基づき展開される鉄道予知保全ソリューションには、すべての鉄道資産情報を視覚化し、線路の状態を管理、監視、分析する機能が搭載されます。Bentley SystemsはAssetWiseソリューションの販売、導入、サポートを継続し、Strides Engineeringは保線において培ってきた領域経験とアドオンアプリケーションを展開、提供します。 SMRT Trainsは、Bentley SystemsのYear in Infrastructure 2021で、going digital(デジタル化)推進を紹介するプレゼンテーションの一環として11月に開催される、 「Infrastructure Spotlight Series」ウェビナーに登場します。ご登録に関する情報はyii.bentley.comにて後日ご案内します。SMART Trainsの革新性の詳細を、このウェビナーでぜひご確認ください。 SMRT TrainsプレジデントのLam Sheau Kai氏は、次のように述べています。「テクノロジーの活用と予防措置。この2つは、SMRT Trainsが運行する鉄道の信頼性を向上させ、維持していくうえで非常に重要です。この2つの要素を兼ね備えたPDSSが南北線と東西線に無事導入されたことで、他路線への拡張に向けて大きな弾みがつきました」。 新たなパートナーシップについて、Strides EngineeringプレジデントのGan Boon Jin氏は次のように述べています。「Strides EngineeringとBentley SystemsはPDSSを巡り協力し、固いパートナーシップのもと、豊富な領域経験と鉄道運用能力に実証済みのテクノロジーを組み合わせることができました。PDSSは、保線における意思決定を強化し、最適化します。PDSSのベストプラクティスと成果を、アジア太平洋地域の多くの鉄道事業者に提供できることを楽しみにしています」。 Bentley Asia SouthのバイスプレジデントであるKaushik…

BUSINESS: General Micro Systems (GMS), Introduces “4×4” Quad Artificial Intelligence GPGPU Server For Defense And Government Applications
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: General Micro Systems (GMS), Introduces “4×4” Quad Artificial Intelligence GPGPU Server For Defense And Government Applications

WASHINGTON–(BUSINESS WIRE)–General Micro Systems today launched its Velocity “4×4” quad GPGPU artificial intelligence (AI) server designed for battlefield applications like command posts, tactical operation centers (TOCs) and protected platforms such as autonomous vehicles, wide body airborne sensor fusion, surveillance, data mining, synthetic vision and any platform than needs massive computational resources from a small, air-cooled…

BUSINESS: New Data On RYBREVANT(R) (Amivantamab-Vmjw) In Combination With Lazertinib Show Early Activity In Patients With Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib And Platinum-Based Chemotherapy
| | | | | | | | | | | | | | | |

BUSINESS: New Data On RYBREVANT(R) (Amivantamab-Vmjw) In Combination With Lazertinib Show Early Activity In Patients With Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib And Platinum-Based Chemotherapy

RARITAN, N.J., Sept. 19, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose…

BUSINESS: RYBREVANT(R) (Amivantamab-Vmjw) Provides Higher Activity And Longer Duration Of Response When Used In Combination With Lazertinib In Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
| | | | | | | | | | | | | | |

BUSINESS: RYBREVANT(R) (Amivantamab-Vmjw) Provides Higher Activity And Longer Duration Of Response When Used In Combination With Lazertinib In Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib

RARITAN, N.J., Sept. 19, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.1 The analysis showed higher…

BUSINESS: Janssen Presents Results From Phase 1b/2 NORSE Study In Patients With Metastatic Or Locally Advanced Urothelial Carcinoma Treated With BALVERSA® (Erdafitinib) In Combination With Cetrelimab, A PD-1 Inhibitor
| | | | | | | | | | | | | | | |

BUSINESS: Janssen Presents Results From Phase 1b/2 NORSE Study In Patients With Metastatic Or Locally Advanced Urothelial Carcinoma Treated With BALVERSA® (Erdafitinib) In Combination With Cetrelimab, A PD-1 Inhibitor

RARITAN, N.J., Sept. 17, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast…

BUSINESS: North Dakota US Navy Veterans Lung Cancer Advocate Requests A Navy Veteran With Lung Cancer In North Dakota Who Had Been Exposed To Navy Asbestos To Call Attorney Erik Karst At KVO About Compensation
| | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: North Dakota US Navy Veterans Lung Cancer Advocate Requests A Navy Veteran With Lung Cancer In North Dakota Who Had Been Exposed To Navy Asbestos To Call Attorney Erik Karst At KVO About Compensation

    FARGO, ND, September 10, 2021 /24-7PressRelease/ — The North Dakota US Navy Veterans Lung Cancer Advocate is urging the family of a Navy Veteran who has just been diagnosed with lung cancer in North Dakota or anywhere in the nation to please call attorney Erik Karst of the law firm of Karst von Oiste-KVO at…

BUSINESS: North Dakota US Navy Veterans Lung Cancer Advocate Urges A Navy Veteran With Lung Cancer In North Dakota Who Had Navy Asbestos Exposure To Call Attorney Erik Karst Of KVO About Compensation
| | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: North Dakota US Navy Veterans Lung Cancer Advocate Urges A Navy Veteran With Lung Cancer In North Dakota Who Had Navy Asbestos Exposure To Call Attorney Erik Karst Of KVO About Compensation

    FARGO, ND, September 10, 2021 /24-7PressRelease/ — The North Dakota US Navy Veterans Lung Cancer Advocate is urging the family of a Navy Veteran who has just been diagnosed with lung cancer in North Dakota or anywhere in the nation to please call attorney Erik Karst of the law firm of Karst von Oiste-KVO at…

Technology:  GB Decides 212
| | | | | | | | | | |

Technology: GB Decides 212

Jeff Grubb@jeffgrubb September 3, 2021 2: 29 PM A new GamesBeat event is around the corner! Find out more about the next GamesBeat event. GamesBeat Decides will convene to decide everything in the world of videogames so you don’t have to think for yourselves. GamesBeat editors Mike Minotti & Jeff Grubb discuss the recently announced…

Marquis Who's Who Honors Frank Mann with Inclusion in Who's Who in the World
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Marquis Who's Who Honors Frank Mann with Inclusion in Who's Who in the World

    NEW YORK, NY, May 10, 2021 /24-7PressRelease/ — Marquis Who’s Who, the world’s premier publisher of biographical profiles, is proud to honor Frank Mann with inclusion in Who’s Who in the World. An accomplished listee, Frank Mann celebrates many years’ experience in his professional network, and has been noted for achievements, leadership qualities, and the…

End of content

End of content